Inactive Instrument

Acacia Pharma Group plc

Equities

ACPH

GB00BYWF9Y76

Acacia Pharma : Publication of Annual Report 2020

March 30, 2021 at 01:00 am EDT

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Acacia Pharma Group plc Publishes its Annual Report and Financial Statements for the Year ended 31 December 2020

Cambridge, UK and Indianapolis, US – 30 March 2021, 07:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2020.

The Annual Report is attached here and also available on www.acaciapharma.com in the Investors/Financial Reports and Presentations section.

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO +44 1223 919760 / +1 317 505 1280 IR@acaciapharma.com	International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson +44 20 7638 9571 acaciapharma@citigatedewerogerson.com
US Investors LifeSci Advisors Irina Koffler +1 917-734-7387 ikoffler@lifesciadvisors.com	Media in Belgium and the Netherlands Chris Van Raemdonck +32 499 58 55 31 chrisvanraemdonck@telenet.be

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS^® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

www.acaciapharma.com

Attachment

Acacia Pharma Group plc Annual Report and Financial Statements for the Year ended 31 December 2020

Latest news about Acacia Pharma Group plc

Eagle Pharmaceuticals Completes Acacia Pharma Acquisition	22-06-09	MT
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist	22-06-09	MT
Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index	22-06-08	CI
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion	22-06-07	MT
Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders.	22-06-05	CI
Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Sector Update: Health Care Stocks Posting Modest Gains Monday	22-03-28	MT
Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup	22-03-28	DJ
Sector Update: Health Care Stocks Still Looking for Monday Direction	22-03-28	MT
Sector Update: Health Care	22-03-28	MT
FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks	22-03-28	DJ
FTSE 100 Rises, 10Y Gilt Yields Hit Six-Year High as Interest-Rate Rises Loom	22-03-28	DJ
FTSE Rises, Rolls-Royce Slides as Takeover Talk Remains Unconfirmed	22-03-28	DJ
FTSE 100 Rises on Optimism Over Russia-Ukraine Talks	22-03-28	DJ
Eagle Pharmaceuticals to Acquire Acacia Pharma	22-03-28	MT
Sterling Weakens Vs In-Favor Dollar, Could Drop Toward $1.30	22-03-28	DJ
Acacia Pharma Accepts $104 Million Takeover Bid from US-Based Eagle Pharmaceuticals	22-03-28	MT
Eagle Pharmaceuticals, Inc. entered into an agreement to acquire Acacia Pharma Group plc from a group of shareholders for €89.8 million.	22-03-27	CI
Acacia Pharma CFO To Step Down	22-03-23	MT
Gary Gemignani to Leave Acacia Pharma Group plc as Chief Financial Officer	22-03-23	CI
Acacia Pharma Completes US FDA's Required Study for Post-Operative Drug With No Adverse Events	21-12-13	MT
Acacia Pharma Completes Required Barhemsys Clinical Trial	21-12-13	DJ
Acacia Pharma Announces Successful Completion of Barhemsys® Post-Approval Requirement Study in Patients with Severe Renal Impairment	21-12-13	CI
ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...	21-10-01

Chart Acacia Pharma Group plc

Duration

Period

More charts

Company Profile

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Sector

More about the company